Introduction {#Sec1}
============

Psychosis intrinsic to Parkinson's disease {#Sec2}
------------------------------------------

Over the past decade, following the formulation of operational criteria for the diagnosis of psychosis in Parkinson's disease (PD) \[[@CR1]\], there has been a resurgence of interest in this 'nonmotor' aspect of the disorder \[[@CR2]\]. With the historical literature on PD failing to clearly identify a typical psychotic syndrome in the pre-levodopa era in the absence of other known precipitating factors \[[@CR3], [@CR4]\], the onset of psychosis in PD was initially related to treatment with levodopa and, subsequently, with dopamine receptor agonists \[[@CR5]\].

However, definitively disentangling the effects of medication and disease requires contemporary studies of patients with untreated disease over the longitudinal course \[[@CR6]\], which presents both ethical and practical challenges. In relation to PD, these challenges can be overcome through the assessment of drug-naive patients at their first presentation and, in developing countries where health service provision is as yet insufficient, over the continuing course of untreated illness. Critically, findings in these drug-naive states indicate that psychosis can be detected in PD at first presentation \[[@CR7]\] and for several years thereafter \[[@CR8]\]. Thus, echoing earlier theorizing \[[@CR9]\], contemporary theory posits that levodopa/dopamine (DA) D~2~ receptor agonist treatment interacts with the disease process in the manner of a 'modifier' that 'unmasks' psychosis intrinsic to PD \[[@CR2]\]. Importantly, this same review \[[@CR2]\] recognizes the unmet need for an analysis of psychotic psychopathology in PD and its putative pathobiology vis-à-vis psychosis across other conditions. The present article presents such an analysis in juxtaposition with schizophrenia spectrum and related psychotic disorders, the essential elements of which are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Comparison of phenomenological, pharmacological and pathobiological features of Parkinsonʼs disease and schizophreniaCharacteristicParkinson's diseaseSchizophrenia*Movement disorder*Age at diagnosisPrimarily in the elderly, but can occur at any age from youthPrimarily in youth, but can occur through to old agePhenomenology (drug-naive)Bradykinesia/akinesia, rigidity, tremor, postural/gait impairmentBradykinesia/akinesia, rigidity, tremor, postural/gait impairment, AIMEffect of levodopaAntiparkinsonian actionUnknown due to absence of trials in otherwise drug-naive patientsEffect of antipsychoticsExacerbation of movement disorder \[FGA \> SGA \> clozapine\]Exacerbation/induction of movement disorder \[FGA \> SGA \> clozapine\]*Psychosis*Age at diagnosisPrimarily in the elderly, but can occur at any age from youthPrimarily in youth, but can occur through to old agePhenomenology (drug-naive)VH \> AH \> DEL but all domains of psychosis may be encountered, with no points of rarity vis-à-vis schizophreniaAH = DEL \> VH but all domains of psychosis may be encountered, with no points of rarity vis-à-vis PDEffect of levodopaExacerbation/induction of psychosisUncertain due to paucity of controlled trials in otherwise drug-naive patientsEffect of antipsychoticsAntipsychotic action \[clozapine \> SGA \> FGA\]Antipsychotic action \[clozapine \> SGA \> FGA\]*Nonmotor/nonpsychotic features*Subclinical psychotic experiences/ideation, depressionSubclinical psychotic experiences/ideation, depression*Progression*Movement disorderNeurodegenerative process; natural course as per historical record now confounded by levodopa treatment and emergence of dyskinesia and on-off effectsNatural course of intrinsic movement disorder unclear; confounded by antipsychotic treatment and emergence of drug-induced parkinsonism and tardive dyskinesia \[FGA \> SGA \> clozapine\]PsychosisNatural course of intrinsic psychosis unclear; confounded by exacerbation/induction of psychosis by levodopa treatmentNeurodevelopmental process; natural course as per historical record now confounded by antipsychotic treatment*Genetics*No evidence from GWAS for shared genetic risk with schizophrenia; 22q11.2 microdeletions associated with risk for schizophrenia as well as PDNo evidence from GWAS for shared genetic risk with PD; 22q11.2 microdeletions associated with risk for PD as well as schizophrenia*Pathobiology*NeuropathologyDegeneration of nigrostriatal DA neurons with loss of striatal DA; deposition of Lewy bodiesIntegrity of nigrostriatal DA neurons and striatal DA; cytoarchitectural evidence for dysplasiaNeuroimagingPrimary loss of DA in dorsal putamen and relative preservation in caudateHyperactivity in nigrostriatal DA neurons, with primary hyperfunction in dorsal caudate and less so in putamenNetwork dysfunctionDAergic hypofunction with disruption to one or more elements in a cortical-striatal-thalamocortical network?DAergic hyperfunction with disruption to one or more elements in a cortical-striatal-thalamocortical network?*AIM* abnormal, involuntary movements (hyperkinesia/dyskinesia), *FGA* first-generation antipsychotics, *SGA* second-generation antipsychotics, *VH* visual hallucinations, *AH* auditory hallucinations, *DEL* delusions, *PD* Parkinson's disease, *GWAS* genome-wide association studies, *DA* dopamine.

Parkinsonism intrinsic to schizophrenia spectrum psychotic disorders {#Sec3}
--------------------------------------------------------------------

In recent decades, there has been a resurgence of interest in the 'motor' aspects of schizophrenia and related psychotic disorders, culminating in a special issue of the journal *Schizophrenia Research* devoted to this topic \[[@CR10]\]. Although the historical literature on schizophrenia (now schizophrenia-spectrum psychosis, for which schizophrenia is used here as shorthand) in the preneuroleptic era clearly identified movement disorders as an intrinsic component of the disease process \[[@CR11]--[@CR13]\], the introduction of neuroleptic (DA D~2~ receptor antagonist) drugs \[now first-generation antipsychotics (FGAs)\] in the 1950s resulted in this literature being usurped by the presumption that movement disorders in schizophrenia, including parkinsonism, constitute an anti-DAergic side effect of such medication \[[@CR14]--[@CR16]\]; furthermore, this proposition has endured into the era of second-generation antipsychotics (SGAs) \[[@CR17], [@CR18]\].

However, as for psychosis in PD, definitively disentangling the roles of disease and medication requires contemporary studies of untreated schizophrenia over its longitudinal course, which presents comparable ethical and practical challenges. These challenges can be overcome through the assessment of drug-naive schizophrenia patients at their first presentation and, in developing countries where health service provision is as yet insufficient, over the continuing course of untreated illness. Critically, findings in these drug-naive states indicate that movement disorders, both parkinsonism and hyperkinesia, can be detected in schizophrenia at the first presentation and for several years thereafter \[[@CR19]--[@CR24]\]. Thus, we have posited that DA D~2~ receptor antagonist antipsychotics, both FGAs and, although perhaps less so, SGAs, interact with the disease process in the manner of a modifier that 'precipitates' and 'accentuates' movement disorders intrinsic to schizophrenia \[[@CR20], [@CR25]\].

Nosological challenges {#Sec4}
======================

That both psychosis in the movement disorder PD and parkinsonism in the psychotic disorder schizophrenia were initially related to their respective medications but are now recognized to be intrinsic to each disorder clearly indicates overlapping phenomenology. There might appear to be limited scope for diagnostic uncertainty in distinguishing clinically between these two disorders, with the neurodegenerative disorder PD emerging primarily in old age \[[@CR26]\] and the neurodevelopmental disorder schizophrenia emerging primarily in young adulthood \[[@CR27], [@CR28]\]. However, in reality, these present challenges to operational diagnostic algorithms that are further accentuated by the increasing recognition of early-onset (both juvenile and young onset) PD \[[@CR29], [@CR30]\] and both late- and very-late-onset schizophrenia \[[@CR31], [@CR32]\].

The Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease \[[@CR33]\] proceed in two stages: (i) a clinical, phenomenological diagnosis of parkinsonism and (ii) the absence of nine exclusion criteria. These exclusion criteria include the following: "5. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism", which would exclude cases of schizophrenia with parkinsonism in the course of treatment with antipsychotics, and "9. Documentation of an alternative condition known to produce parkinsonism and plausibly connected to the patient's symptoms, or, the expert evaluating physician, based on the full diagnostic assessment feels that an alternative syndrome is more likely than PD", which could, but would not necessarily, exclude cases of schizophrenia with parkinsonism that are not receiving treatment with antipsychotics. The presence of psychosis in PD requires the exclusion of other neuropsychiatric conditions in which psychosis is encountered, including schizophrenia-spectrum disorders and \[nonmedical\] substance-induced psychosis, with the presence or absence of medical treatment with levodopa and/or dopamine receptor agonists specified as an associated feature of psychosis in PD \[[@CR1]\].

Both DSM-IV and DSM-5 recognize the difficulty in distinguishing iatrogenic movement disorders in schizophrenia, such as antipsychotic drug-induced parkinsonism, from the development of idiopathic movement disorders, such as PD. This is exemplified by the long-standing conundrum of whether the emergence of parkinsonism in older patients with schizophrenia who are receiving treatment with antipsychotics reflects antipsychotic drug-induced parkinsonism or the coemergence of PD \[[@CR34]\].

Furthermore, it is well recognized (DSM-IV/5) that psychosis similar to that observed in schizophrenia spectrum psychotic disorders can be encountered in a variety of other medical circumstances \[subject to the exclusion of *substance-induced psychotic disorder*\] under the diagnostic criteria for *psychotic disorder due to a general medical condition*; specific examples given include cerebral neoplasia, cerebral trauma, cerebrovascular disease, epilepsy, Huntington's disease, multiple sclerosis, and central nervous system infections. In our own study of 432 subjects experiencing their first psychotic episode, we identified 13 patients with a DSM-IV diagnosis *of psychotic disorder due to a general medical condition*; these patients had cerebral neoplasia, cerebral trauma, cerebrovascular disease, epilepsy and multiple sclerosis \[[@CR35], [@CR36]\]. As an example, psychosis following a stroke is well recognized as falling within the category of *psychotic disorder due to a general medical condition* \[[@CR37]\], which prompts the following question: why is psychosis in PD not included among the range of conditions exemplifying this category or encountered in our own real-world clinical study? This may reflect, at least in part, the fact that psychosis in PD arises and is most commonly managed within neurology and geriatric services \[[@CR38]\]; in contrast, child and adolescent, adult, old-age or liaison psychiatric services commonly provide care for schizophrenia and psychosis in patients with general medical conditions other than PD. Nevertheless, nosological challenges remain.

Pathobiological challenges {#Sec5}
==========================

Presumption of heterogeneity {#Sec6}
----------------------------

At the level of phenomenology, both psychosis in the movement disorder PD and parkinsonism in the psychotic disorder schizophrenia are now recognized to be intrinsic to each disorder in a manner that can be unrelated to adverse effects of medication. The nosological challenges that this presents are predicated on a presumption that diagnostic criteria seek to distinguish between two independent disorders having distinct pathobiologies and treatments.

Psychosis {#Sec7}
---------

In schizophrenia, the cardinal diagnostic symptoms of psychosis (DSM-IV/5) involve hallucinations, commonly auditory but extending to multimodal experiences, and delusions \[[@CR39]--[@CR41]\]. In PD, visual hallucinations (VH) have been reported to occur more commonly than auditory hallucinations (AH), with the most recent meta-analysis of data from 1970 to 2017, using diverse criteria, indicating that VH occur in 28% and AH occur in 9% of PD patients; for comparison, this meta-analysis also indicates that VH occur in 62% and AH occur in 31% of patients with Lewy body dementia \[[@CR42]\]. However, all but two of the studies reviewed did not involve the NINDS-NIMH diagnostic criteria for psychosis in PD \[[@CR1]\]. The two studies applying these criteria reported (i) one or more hallucinations (in any modality) and/or delusions in 43% of cases, with AH in 18%, VH in 16%, tactile in 12%, olfactory in 11%, and delusions in 4% \[[@CR43]\], and (ii) one or more hallucinations (in any modality) and/or delusions in 14%, with VH in 7%, AH in 4%, olfactory in 2%, tactile in 1%, and delusions in 3% \[[@CR44]\].

The most recent systematic reviews on the spectrum of psychosis in PD further indicate that the prior accentuation of VH may have been overstated, necessitating a broader, more multimodal concept of hallucinations and delusions \[[@CR45], [@CR46]\]. It should be emphasized that any differences in hallucinations and/or delusions between PD and schizophrenia are quantitative variations rather than qualitative distinctions, such that essentially all forms and permutations of such symptoms can be evident in both diagnoses with no points of rarity between them \[[@CR41]\].

Movement disorder {#Sec8}
-----------------

In PD, the cardinal diagnostic symptoms of this movement disorder (Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease) involve bradykinesia/akinesia, rigidity, resting tremor and abnormalities of posture and gait \[[@CR26], [@CR33]\]. In drug-naive schizophrenia, parkinsonism is characterized by these same features \[[@CR19]--[@CR24]\]. However, movement disorders in drug-naive schizophrenia can also include abnormal involuntary movements (AIM) that overlap phenomenologically with what would be described as tardive dyskinesia in schizophrenia patients who have received long-term treatment with antipsychotics \[[@CR12], [@CR19]--[@CR24]\] and dyskinesia in PD patients who have received long-term treatment with L-dopa \[[@CR26]\]. Furthermore, parkinsonism and AIM can occasionally cooccur in patients with drug-naive schizophrenia; in such instances, it appears that while parkinsonism is evident primarily in peripheral regions, AIM have a primarily orofacial topography \[[@CR19]--[@CR24]\].

Broadening the relationships {#Sec9}
----------------------------

There are additional examples of relationships between PD and schizophrenia. At the level of phenomenology, it appears that hallucinations in PD and parkinsonism in drug-naive schizophrenia may each be associated with cognitive deterioration \[[@CR47], [@CR48]\]. At the level of genetics, while a recent meta-analysis of genome-wide association studies (GWASs) across 25 brain disorders failed to indicate shared genetic risk between PD and schizophrenia \[[@CR49]\], microdeletions at 22q11.2 are associated with an increased risk for both PD-like movement disorder \[[@CR50], [@CR51]\] and schizophrenia \[[@CR52]\].

These relationships between PD and schizophrenia-spectrum psychosis present fundamental pathobiological challenges: in PD, each postmortem neurochemical measure of DA and in vivo neuroimaging of fluorodopa and the DA transporter indicate degeneration of nigrostriatal DAergic neurons in the substantia nigra pars compacta with loss of DA from the caudate and putamen \[[@CR26], [@CR53]\], while in schizophrenia, the same measures indicate that nigrostriatal DAergic neurons are intact and hyperactive \[[@CR54], [@CR55]\]. However, an alternative perspective embraces these phenomenological commonalities and interrelationships and invokes a broader concept of systems/network-based pathobiology that seeks integration within an overarching schema.

Overlapping network dysfunction {#Sec10}
-------------------------------

While psychosis involves domains of psychopathology that may appear to differ across various circumstances \[e.g., VH are more prominent in PD, while AH and delusions are more prominent in schizophrenia; complex, multimodal hallucinations and delusions occur in epilepsy, and delusions follow stroke; VH can occur consequent to lysergic acid diethylamide treatment, and schizophrenia-like hallucinations and delusions can occur consequent to treatment with phencyclidine\], the evidence \[[@CR2], [@CR37], [@CR39], [@CR56]--[@CR60]\] shows that these variations are quantitative rather than qualitative, with essentially all domains of psychosis being encountered to some extent in each condition \[[@CR41]\]. This implies some commonality in the neuronal dysfunction that underlies psychosis across such a breadth of circumstances. Furthermore, in each condition, no neuronal pathway functions in isolation; rather, each pathway functions within one or more neuronal networks of interacting regions, the overall functional integrity of which can be disrupted via disturbances in any one or more of the multiple regions involved in that network.

Using schizophrenia as an example, the actions of the DA-releasing drug amphetamine to induce schizophrenia-like psychosis and DA receptor antagonists to exert antipsychotic activity initially led to the proposal that the pathophysiology of psychosis involved DAergic hyperactivity; furthermore, given the classic presumption of a primary role for the nigrostriatal DAergic pathway and the striatum (caudate, putamen, and globus pallidus) in motor function, such hyperactivity in psychosis was related to mesolimbic/mesocortical DAergic pathways \[[@CR61]\]. However, regardless of how persuasive the indirect evidence appeared, these issues remained conjectural in the absence of direct measurements of DAergic function in living patients.

When such measurements became available through positron emission tomography (PET)- and single photon emission computed tomography (SPECT)-based techniques, the results were unexpected: while DAergic hyperfunction in schizophrenia was confirmed, primarily through the D~2~ receptor, this was most evident in the caudate and putamen, with the greater resolution of the most recent studies indicating a large increase in the dorsal (associative and sensorimotor) regions and less so in the ventral (limbic) subdivision of the striatum \[[@CR62]\]. In parallel, the normal functional anatomy of the striatum was recognized to involve (a) midbrain DAergic projections from the ventral tegmental area and medial substantia nigra to the limbic striatum and from the central/ventrolateral substantia nigra to the associative and sensorimotor striatum and (b) three corticostriatal loops that can act independently, interact with each other, and participate in cortico-striato-thalamocortical loops: premotor/motor cortex projections to the caudal putamen; dorsolateral prefrontal cortex (PFC) projections to the associative and sensorimotor striatum; and limbic area (amygdala, hippocampus, ventromedial PFC, and orbitomedial PFC) projections to the limbic striatum \[[@CR55], [@CR63]\]. These findings complement and elaborate extensive evidence from structural and functional magnetic resonance imaging (MRI) studies, including diffusion-tensor imaging tractography, and a broader range of PET, SPECT and neuropsychological investigations; integration of these findings now implicates dysfunction in a prefrontal/anterior cingulate cortical-striatal-hippocampal neuronal network in the pathobiology of schizophrenia and antipsychotic drug action \[[@CR55], [@CR64]--[@CR67]\].

Against this background, it is notable that not only has the DAergic pathobiology of PD become better understood but it is also increasingly recognized to extend beyond DAergic processes. The greatest loss of DAergic neurons is from the ventrolateral substantia nigra with the attendant loss of projections to the dorsal putamen, resulting in the primary movement disorder in PD and relative preservation of DAergic terminals in the caudate \[[@CR26], [@CR30]\]. However, the loss of DAergic neurons can extend to the dorsal substantia nigra and ventral tegmental area with a loss of DA beyond the striatum to include the limbic and cortical regions; these abnormalities can be accompanied by the striatal and extrastriatal loss of serotonergic, noradrenergic and cholinergic neurons \[[@CR68]--[@CR71]\]. Importantly, extranigral and extrastriatal dysfunction in PD is further indicated by the presence of Lewy body pathology in the amygdala, hippocampus and frontal, temporal, parietal, cingulate and occipital cortices and pathways \[[@CR26]\]. While it has been suggested that VH in PD may involve Lewy body deposition in the occipital cortex and associated visual pathways \[[@CR2], [@CR72]\], it is evident that Lewy bodies are also deposited in several components of the cortical-striatal-thalamocortical network discussed here, and there is evidence that hallucinations in PD are associated with striatal DAergic dysfunction \[[@CR73]\].

Given the long-standing recognition of cortical-striatal-thalamocortical loops \[[@CR63]\], a recent study has integrated and interpreted these features in the pathobiology of PD \[[@CR74], [@CR75]\] in the following terms: (a) a dysfunctional cortical-subcortical neuronal network that includes the putamen and mediates predominantly motor dysfunction and (b) a dysfunctional cortico-striato-thalamocortical neuronal network that includes the caudate, frontal association cortex, limbic system and other neocortical areas, and is involved in mediating both motor and nonmotor features intrinsic to PD, such as psychosis \[[@CR2], [@CR30]\]. This model overlaps with dysfunction in the prefrontal/anterior cingulate cortical-striatal-hippocampal neuronal network posited in the pathobiology of psychosis and antipsychotic drug action in schizophrenia \[[@CR55], [@CR64]--[@CR67]\]. In a complementary manner, it has been proposed that hypokinetic movement disorders intrinsic to schizophrenia, such as parkinsonism, involve dysfunction in the cingulate motor cortex/supplementary motor area/motor cortical-striatal-thalamocortical neuronal network \[[@CR76]\].

Critically, there is a precedent for both DAergic hypofunction, a characteristic of PD, and DAergic hyperfunction, a characteristic of schizophrenia, having a common functional effect on an element of the cortico-striato-thalamocortical neuronal network: working memory and executive function mediated via the PFC is critically dependent on the level of prefrontal DAergic activity in the manner of an inverted U-shaped relationship, such that either DAergic hypofunction or DAergic hyperfunction leads to PFC dysfunction and impairment in these domains of cognition \[[@CR77]\]. Similar relationships may be relevant for the present issues of movement disorders and psychosis in PD and schizophrenia. A recent meta-analysis of the neuroimaging literature further indicates that hallucinations in neurodegenerative disorders (including PD) and psychiatric disorders (including schizophrenia) appear to involve structural networks that each include elements of the cortico-striato-thalamocortical network at issue here \[[@CR78]\].

Synthesis {#Sec11}
=========

As overall functional integrity in any cortico-striatal-thalamocortical network can be disrupted via disturbances in any one or more of the regions participating in that network, it follows that both parkinsonian features and psychosis in both PD and schizophrenia could arise through disturbances in different elements of such network circuitry. Following the conceptual and initial systematic outline of cortical-striatal-thalamocortical networks \[[@CR63]\], subsequent detailed elaborations are available descriptively and diagrammatically in the contexts of both PD \[[@CR74], [@CR75]\] and schizophrenia \[[@CR55]\]. Furthermore, variations in the relative preponderance of individual parkinsonian features and modality of hallucinations and nature of delusions might be expected due to variations in the location and severity of those disturbances. Notably, cortical-striatal-thalamocortical neuronal network dysfunction has been implicated not only in PD and schizophrenia but also in substance-induced psychosis \[[@CR79]\], psychosis subsequent to stroke \[[@CR37]\] and psychosis in epilepsy \[[@CR80]\]. In addition, it has been proposed for psychotic illness on the basis of the juxtaposition of clinical findings with preclinical and computational neuroscience considerations \[[@CR81]\].

It appears that the following varying modes of disturbance to one or more element(s) in the cortical-striatal-thalamocortical neuronal network can result in movement disorders, psychosis or both: neurodegenerative, neurodevelopmental, substance abuse, cerebrovascular disease, or seizure activity. This would also appear to be relevant to other forms of cerebral abnormality: trauma, where we have reported the most common finding with schizophrenia-like psychosis to be damage to the temporal cortex \[[@CR82]\]; multiple sclerosis, where the most common finding with psychosis is white matter lesions in fronto-temporal regions \[[@CR83]\]; and Alzheimer's disease, where the most common finding with psychosis is abnormalities in dorsolateral PFC, with some reports also implicating anterior cingulate cortex and ventral striatal regions \[[@CR84], [@CR85]\]. In other disorders in which disruption to elements in a cortical-striatal-thalamocortical neuronal network is pathognomonic and psychosis can be encountered, such as frontotemporal dementia \[[@CR86], [@CR87]\] and Huntington's disease \[[@CR88]\], it will be a task for future studies to further clarify the relationship between psychosis and such network disruption. This challenge also applies to psychosis that is consequent to cerebral neoplasia \[[@CR89]\] and the extent to which such psychosis might be associated with movement disorders.

While these systems-based considerations relate to overt neurological and psychiatric disorders in which movement disorders and psychosis can be encountered, they are also of interest in the context of other overlapping clinical features of PD and schizophrenia. In PD, it is well known that nonmotor features extend beyond psychosis to include depression \[[@CR72]\], while in schizophrenia, nonpsychotic features are well known to extend beyond movement disorders to include depression \[[@CR90]\]. Notably, recent evidence indicates psychosis and depression involve shared network dysfunction that overlaps with the cortical-striatal-thalamocortical network posited above \[[@CR64], [@CR67], [@CR91], [@CR92]\].

Subclinical features of disorders might facilitate early detection and hence early intervention to improve long-term outcomes. Thus, it is striking that (a) 'minor' (subclinical) psychotic experiences/ideation and depression may be early nonmotor symptoms in younger persons that can predate the onset of overt PD \[[@CR7], [@CR93]\], and (b) (subclinical) psychotic experiences/ideation and depression can be present in younger persons in the general population and may be prodromal indicators of the risk for overt schizophrenia \[[@CR90], [@CR94], [@CR95]\]. Such findings further elaborate the relationship between PD and schizophrenia, summarized in Table [1](#Tab1){ref-type="table"}, that might be best accommodated within a model of time- and site-dependent variations in the severity of dysfunction within a common cortical-striatal-thalamocortical neuronal network.
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